Cephalon

Mar 20, 08
	NEW STORY
11:30 ET	Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
Feb 19, 08
08:30 ET	FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
Feb 14, 08
10:00 ET	Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting
Feb 13, 08
16:55 ET	Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
Feb 12, 08
16:10 ET	Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance
Feb 08, 08
09:08 ET	Cephalon General Counsel John E. Osborn to Resign Position
Jan 25, 08
12:00 ET	Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Jan 24, 08
14:15 ET	Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
Jan 08, 08
14:08 ET	Cephalon Quarterly Conference Call Invitation
Jan 07, 08
11:30 ET	Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
Jan 04, 08
15:15 ET	Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
Dec 31, 07
10:30 ET	Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Dec 10, 07
08:47 ET	TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
08:44 ET	TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Dec 03, 07
08:30 ET	TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
Nov 12, 07
08:30 ET	Cephalon Submits Supplemental New Drug Application for FENTORA
Nov 08, 07
16:30 ET	Cephalon Announces Strong Third Quarter Financial Results
Nov 01, 07
17:43 ET	Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
Oct 23, 07
16:30 ET	Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma
Oct 01, 07
15:00 ET	Cephalon Quarterly Conference Call Invitation
Sep 21, 07
08:00 ET	Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Sep 17, 07
08:00 ET	Cephalon Announces Completion of Anticipated PROVIGIL Label Updates
Sep 13, 07
14:11 ET	Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Aug 29, 07
16:30 ET	FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
Aug 23, 07
08:59 ET	Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
Aug 16, 07
07:00 ET	Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Jul 31, 07
16:31 ET	Cephalon Reports Strong Sales for Second Quarter 2007
Jun 28, 07
09:00 ET	Cephalon Announces Plans for New NDA Filing for TREANDA(R)
Jun 26, 07
16:30 ET	Cephalon, Inc. to Webcast Research and Development Day
12:00 ET	Cephalon Quarterly Conference Call Invitation
Jun 18, 07
06:55 ET	Cephalon Receives FDA Approval of NUVIGIL(TM) for the Treatment of Excessive Sleepiness Associated with Three Disorders
May 31, 07
09:00 ET	Cephalon, Inc. Added to NASDAQ-100 Index
May 16, 07
15:21 ET	Cephalon General Counsel John Osborn Nominated by President Bush to Serve on the United States Advisory Commission on Public Diplomacy
May 15, 07
13:16 ET	U.S. Government Organizations Release Positive Information About VIVITROL(R) for the Treatment of Alcoholism
May 01, 07
16:30 ET	Cephalon First Quarter Earnings Increase Dramatically
11:30 ET	Cephalon Presents Positive Results for FENTORA(R) in Breakthrough Pain Associated with Neuropathic Conditions
Apr 25, 07
18:47 ET	Cephalon Expects First Quarter 2007 Results to Exceed Expectations
Mar 30, 07
16:51 ET	Cephalon Provides Update Related to NUVIGIL(TM) New Drug Application
Mar 27, 07
13:00 ET	Cephalon Quarterly Conference Call Invitation
Mar 26, 07
16:30 ET	Cephalon Files Marketing Application for Approval of a Fentanyl Effervescent Buccal Tablet in Europe
Feb 28, 07
08:00 ET	Great Valley Regional Chamber of Commerce Profile Awards Dinner to be held Thursday March 22, 2007 at The Desmond Hotel and Conference Center in Malvern
Feb 12, 07
16:30 ET	Cephalon Reports Record Sales and Earnings for 2006
Feb 07, 07
11:34 ET	Cephalon, Inc. Promotes Mike Barr to Vice President
Jan 26, 07
10:35 ET	Cephalon Changes Quarterly Conference Call Date
Jan 24, 07
16:10 ET	Cephalon Comments on Study of its Leukemia Treatment Led by National Cancer Institute Cooperative Group
Jan 16, 07
09:22 ET	Cephalon Quarterly Conference Call Invitation
Jan 09, 07
13:59 ET	Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
Jan 08, 07
08:23 ET	Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
Dec 19, 06
07:30 ET	Cephalon Reduces Outstanding Convertible Debt by $337 Million
Dec 07, 06
08:00 ET	Cephalon Provides Update Related to Final NUVIGIL(TM) Labeling
Dec 04, 06
13:00 ET	Cephalon, Inc. Appoints Dr. Raj Khankari as General Manager of CIMA LABS
Nov 07, 06
14:51 ET	Cephalon Inc. Granted Composition of Matter Patent Covering NUVIGIL(TM)
Nov 02, 06
16:30 ET	Cephalon Third-Quarter Earnings More Than Double
Nov 01, 06
12:37 ET	Dial-in Numbers Changed for Cephalon Quarterly Conference Call
Oct 11, 06
09:24 ET	Cephalon Announces Positive Results for FENTORA(TM) (fentanyl buccal tablet) for Breakthrough Pain in Patients with Chronic Low Back Pain
Oct 05, 06
14:13 ET	Cephalon Quarterly Conference Call Invitation
Sep 25, 06
18:11 ET	Cephalon Receives FDA Approval of FENTORA(TM) (fentanyl buccal tablet) for the Management of Breakthrough Pain in Patients with Cancer
Aug 25, 06
09:00 ET	Cephalon, Inc. Appoints Dr. Lesley Russell as Senior Vice President Worldwide Medical and Regulatory Operations
Aug 09, 06
17:01 ET	Cephalon Receives Non-Approvable Letter on SPARLON(TM)
Aug 03, 06
16:30 ET	Cephalon Second-Quarter Sales Increase 58 Percent
Jul 26, 06
16:35 ET	Cephalon Expects Second Quarter 2006 Results to Exceed Prior Guidance
Jun 29, 06
17:20 ET	Cephalon Receives Approvable Letter for FENTORA(TM) (fentanyl buccal tablet) for Management of Breakthrough Pain in Patients with Cancer
Jun 26, 06
16:50 ET	Cephalon Announces Results from GABITRIL(R) Clinical Program in Generalized Anxiety Disorder
Jun 21, 06
14:41 ET	Cephalon Quarterly Conference Call Invitation
Jun 19, 06
12:13 ET	CIMA LABS Drug Delivery Technology Used in Orapred ODT(TM)
Jun 13, 06
08:00 ET	VIVITROL, the First, Once-Monthly Injectable Medication for Alcohol Dependence Now Available in the United States
Jun 12, 06
16:30 ET	Cephalon and Takeda Announce Agreement to Co-Promote PROVIGIL(R) in the United States
May 17, 06
16:30 ET	Cephalon Appoints Ambassador Kevin E. Moley to Board of Directors
May 04, 06
08:00 ET	Cephalon's Fentanyl Effervescent Buccal Tablet Reduces Intensity of Breakthrough Pain in Cancer Patients
May 02, 06
16:30 ET	Cephalon Reports First-Quarter Financial Results
May 01, 06
16:45 ET	Cephalon Receives Approvable Letter for NUVIGIL(TM) (armodafinil)
Apr 24, 06
17:18 ET	Cephalon, Inc. Provides Update on Regulatory Status of SPARLON(TM)
Apr 07, 06
09:05 ET	Cephalon Quarterly Conference Call Invitation
Apr 04, 06
08:05 ET	Cephalon Oncology Compound Lestaurtinib (CEP-701) Granted Orphan Drug Designation for Acute Myeloid Leukemia
Mar 28, 06
08:02 ET	Cephalon Granted Six Months of Pediatric Exclusivity for PROVIGIL(R)
Mar 23, 06
17:36 ET	FDA Advisory Committee Recommends Against Approval of SPARLON(TM) for Attention Deficit/Hyperactivity Disorder in Children and Adolescents
Mar 21, 06
14:40 ET	Cephalon Conference Call Invitation
Feb 14, 06
16:30 ET	Cephalon Reports Outstanding Financial Results for 2005
Feb 01, 06
17:50 ET	Cephalon, Inc. Announces Agreements With Barr Laboratories, Inc. Regarding Settlement of PROVIGIL(R) and ACTIQ(R) Patent Litigations
17:28 ET	Cephalon, Inc. Provides Update on Regulatory Status of NUVIGIL(TM)
Jan 31, 06
14:30 ET	Horst Witzel, Dr.-Ing., to Retire From Cephalon Board of Directors
Jan 25, 06
16:50 ET	Cephalon, Inc. Provides Update on Regulatory Status of SPARLON(TM)
Jan 11, 06
08:48 ET	Cephalon Quarterly Conference Call Invitation
Jan 10, 06
08:02 ET	Cephalon, Inc. Announces Agreement with Mylan Pharmaceuticals Inc. Regarding Settlement of PROVIGIL(R) Patent Litigation
Dec 22, 05
16:01 ET	Cephalon, Inc. Completes Acquisition of Zeneus Holdings Limited
12:00 ET	Cephalon, Inc. Announces Agreement with Ranbaxy Laboratories Limited Regarding Settlement of PROVIGIL(R) Patent Litigation
Dec 16, 05
16:37 ET	Cephalon to Webcast Dec. 19, 2005 Investor Meeting
Dec 12, 05
13:30 ET	Cephalon Oncology Reports Clinical Response to CEP-701 Correlates With Targeted Inhibition of FLT3 Mutation in Acute Myelogenous Leukemia
07:30 ET	Cephalon Oncology Reports High Response Rates to Single Agent TREANDA in Non- Hodgkin's Lymphoma
Dec 09, 05
08:45 ET	Cephalon, Inc. Announces Agreement with Teva Pharmaceutical Industries Ltd. Regarding Settlement of PROVIGIL(R) Patent Litigation
Dec 08, 05
08:50 ET	Scientific Advances on Three Lead Cephalon Oncology Compounds to be Presented at 47th American Society of Hematology Meeting
Dec 06, 05
02:00 ET	Cephalon, Inc. Announces Agreement to Acquire Zeneus Holdings Limited
Dec 05, 05
07:15 ET	Pediatrics Publishes Pivotal Study Showing SPARLON(TM) Significantly Improves ADHD Symptoms in Children and Adolescents
Nov 01, 05
16:02 ET	Cephalon Continues to Deliver Strong Growth in Third Quarter
Oct 21, 05
07:30 ET	Cephalon Receives Approvable Letter for SPARLON(TM) for the Treatment of ADHD in Children and Adolescents
Sep 29, 05
09:37 ET	Cephalon Quarterly Conference Call Invitation
Sep 12, 05
16:00 ET	Cephalon Receives FDA Approval to Market Sugar-Free Formulation of ACTIQ(R)
Sep 06, 05
07:00 ET	Cephalon Files New Drug Application for OraVescent(R) Fentanyl for the Management of Breakthrough Pain in Cancer Patients
Sep 01, 05
06:59 ET	Cephalon, Inc. Announces Agreement With McNeil Consumer & Specialty Pharmaceuticals to Co-Promote ATTENACE(TM) for Attention-Deficit/Hyperactivity Disorder
Aug 31, 05
16:30 ET	Cephalon, Inc. Conference Call Invitation
Aug 30, 05
16:30 ET	Cephalon Receives Approval to Market Modafinil for Shift Work Sleep Disorder in Germany
Aug 25, 05
15:00 ET	CIMA LABS' OraSolv(R) Technology Used in CLARINEX(R) (desloratadine) Reditabs(R) Re-formulation
07:00 ET	Cephalon Board Member Gail Wilensky Appointed to World Health Organization Commission
Aug 03, 05
17:03 ET	New England Journal of Medicine Publishes First Clinical Study of Medication to Improve Wakefulness in Patients with Shift Work Sleep Disorder
Aug 02, 05
16:30 ET	Cephalon Reports Continued Strong Growth in Second Quarter
Jul 19, 05
07:04 ET	Cephalon, Inc. Completes Acquisition of TRISENOX(R) From Cell Therapeutics, Inc.
Jul 13, 05
07:01 ET	Cephalon Announces Executive Appointment; Jeff Myers Named Vice President of Government Affairs
Jul 12, 05
08:45 ET	Cephalon, Inc. Accepts Notes Tendered Pursuant to Offer for 2-1/2 Percent Convertible Subordinated Notes Due December 2006
Jul 01, 05
12:26 ET	Cephalon Announces Exercise of $120 Million Over-allotment Option on Convertible Senior Subordinated Notes
Jun 30, 05
14:09 ET	Cephalon Quarterly Conference Call Invitation
Jun 24, 05
06:00 ET	Cephalon and Alkermes Announce Agreement for the Commercialization of Vivitrex(R) for the Treatment of Alcohol Dependence
Jun 14, 05
16:30 ET	Cephalon, Inc. Completes Acquisition of Salmedix, Inc.
Jun 13, 05
06:55 ET	Cephalon, Inc. Announces Acquisition of TRISENOX(R) from Cell Therapeutics, Inc.
Jun 10, 05
09:19 ET	Cephalon Commences Tender Offer for 2-1/2 Percent Convertible Subordinated Notes Due 2006
Jun 02, 05
09:31 ET	Cephalon Prices $800 Million Public Offering of 2 Percent Convertible Senior Subordinated Notes
Jun 01, 05
16:03 ET	Cephalon Announces Proposed Public Offering of Convertible Senior Subordinated Notes
May 18, 05
16:00 ET	Vaughn M. Kailian Elected to Cephalon Board of Directors
May 12, 05
16:01 ET	Cephalon Announces Acquisition of Salmedix
May 11, 05
16:50 ET	Cephalon and H. Lundbeck Announce Discontinuation of CEP-1347 Clinical Trial in Parkinson's Disease
May 05, 05
08:35 ET	Cephalon Announces Positive Phase 3 Clinical Trial Results for ORAVESCENT(R) Fentanyl
May 03, 05
16:30 ET	Cephalon Reports Continued Strong Earnings Growth
May 02, 05
10:10 ET	Cephalon, Inc. Provides Update on Patent Litigation Matters
Apr 26, 05
09:29 ET	Cephalon Quarterly Conference Call Invitation
Apr 04, 05
16:30 ET	Cephalon Quarterly Conference Call Invitation
Mar 31, 05
15:50 ET	Cephalon Files New Drug Application for NUVIGIL(TM)
Mar 29, 05
08:36 ET	Cephalon, Inc. Moves Corporate Headquarters to Frazer, PA; Chester County Location Fulfills Commitment to Expand in Pennsylvania
Mar 25, 05
09:04 ET	Cephalon Receives Approvable Letter to Market Sugar-Free Formulation of ACTIQ(R)
Mar 04, 05
08:10 ET	Cephalon Announces Executive Appointment
Feb 15, 05
16:30 ET	Cephalon Reports Outstanding Financial Results for 2004
Feb 14, 05
08:47 ET	Cephalon Announces Executive Appointments for European Operations
Feb 10, 05
08:55 ET	Cephalon Announces Positive Clinical Trial Results for NUVIGIL(TM)
Feb 07, 05
16:00 ET	REMINDER: Cephalon Quarterly Conference Call Invitation
Feb 03, 05
16:33 ET	Robert J. Feeney, Ph.D., to Retire from Cephalon Board of Directors
Jan 10, 05
16:30 ET	Cephalon Quarterly Conference Call Invitation
Dec 21, 04
08:25 ET	Cephalon Files Application for Marketing Approval of New Modafinil Formulation for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Dec 16, 04
08:19 ET	Cephalon, Inc. Completes Exchange Offer for Its Zero Coupon Convertible Subordinated Notes Due 2033
Dec 08, 04
13:50 ET	Anticipated Generic ACTIQ Filing Occurs; Cephalon Expects No Change in Barr's Likely Date of Market Entry
Dec 01, 04
08:35 ET	Cephalon Files Supplemental New Drug Application for Sugar-Free Formulation of ACTIQ
Nov 16, 04
14:39 ET	Cephalon, Inc. Commences Exchange Offer for Its Zero Coupon Convertible Subordinated Notes Due 2033
Nov 03, 04
16:31 ET	Cephalon, Inc. Reports Third Quarter Financial Results
Oct 27, 04
10:01 ET	Cephalon Quarterly Conference Call Invitation
Sep 14, 04
09:02 ET	Cephalon Announces Executive Appointments; Vice Presidents Named to Medical Affairs and Intellectual Property
Sep 07, 04
10:39 ET	Cephalon Receives Subpoena from U.S. Attorney's Office
Aug 19, 04
07:00 ET	Cephalon Announces Positive Results with a New Modafinil Formulation for the Treatment of Children with Attention Deficit Hyperactivity Disorder
Aug 12, 04
17:05 ET	Cephalon Completes Acquisition of CIMA LABS INC.
Aug 09, 04
17:28 ET	Cephalon, Inc. and CIMA LABS INC. Announce FTC Clearance to Proceed with Merger
Aug 03, 04
16:30 ET	Cephalon, Inc. Reports Second Quarter Financial Results
Jul 27, 04
09:36 ET	Cephalon Quarterly Conference Call Invitation
Jul 26, 04
15:08 ET	Cephalon Announces Executive Appointments
Jul 01, 04
09:30 ET	Cephalon Quarterly Conference Call Invitation
Jun 30, 04
08:04 ET	Cephalon, Inc. and CIMA LABS INC. Announce Agreement in Principle with FTC Staff on Proposed Merger
May 03, 04
16:30 ET	Cephalon, Inc. Reports First Quarter Financial Results
Apr 27, 04
10:37 ET	Cephalon Quarterly Conference Call Invitation
Apr 13, 04
07:40 ET	Cephalon Receives Broad Label for PROVIGIL in the United Kingdom
07:10 ET	Cephalon Announces Plans for Phase III Anxiety Program for GABITRIL in 2004
Apr 06, 04
15:07 ET	Cephalon to Webcast Analyst Meeting Tuesday, April 13, 2004
Apr 01, 04
09:44 ET	Cephalon Quarterly Conference Call Invitation
Feb 12, 04
16:30 ET	Cephalon, Inc. Reports Record Financial Results for 2003
Feb 06, 04
08:38 ET	Cephalon Files $1.0 Billion Universal Shelf Registration Statement
Feb 05, 04
15:27 ET	Cephalon Quarterly Conference Call Invitation
Feb 04, 04
10:40 ET	Cephalon Appoints Kenneth J. Fiorelli to Vice President, Global Process Development
Jan 26, 04
12:58 ET	Cephalon Announces FDA Approval of Expanded Label of PROVIGIL(R)
Jan 23, 04
16:01 ET	Cephalon, Inc. and CIMA LABS INC. Receive FTC Request for Additional Information
Jan 14, 04
14:07 ET	Cephalon Quarterly Conference Call Invitation
Jan 13, 04
12:09 ET	Cephalon, Inc. Initiates Phase III Clinical Trials for the R-isomer of Modafinil
Nov 03, 03
16:30 ET	Cephalon, Inc. Reports Third Quarter 2003 Financial Results
16:27 ET	Cephalon, Inc. and CIMA LABS INC. Sign Definitive Merger Agreement
Oct 21, 03
07:10 ET	Cephalon Receives Approvable Letter to Broaden PROVIGIL Label
Oct 17, 03
09:17 ET	Cephalon Appoints Victor Raczkowski to Vice President, Regulatory Affairs
Oct 09, 03
15:51 ET	Cephalon Receives Approval for Expanded Use of Modafinil in Germany and the Republic of Ireland
Oct 08, 03
10:50 ET	Cephalon Quarterly Conference Call Invitation
Sep 25, 03
14:32 ET	FDA Advisory Committee Recommends Expanded Label for PROVIGIL; FDA Action on Cephalon, Inc. Application is Expected by Year-end
08:02 ET	Cephalon, Inc. (Nasdaq: CEPH) Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss PROVIGIL sNDA
Sep 23, 03
16:30 ET	Cephalon sNDA Conference Call Invitation
Sep 02, 03
10:55 ET	Cephalon Responds to CIMA LABS Decision
Aug 21, 03
11:58 ET	Cephalon, Inc. Confirms Proposal for CIMA LABS INC. Pending Due Diligence
Aug 04, 03
16:30 ET	Cephalon, Inc. Reports Second Quarter 2003 Financial Results
Jul 28, 03
09:24 ET	Cephalon Quarterly Conference Call Invitation
Jul 07, 03
14:00 ET	Cephalon Quarterly Conference Call Invitation
Jul 01, 03
13:19 ET	Cephalon Names Susan Sullman, Ph.D., as Vice President of Regulatory Affairs-Europe
Jun 17, 03
08:50 ET	Cephalon Calls for Redemption of 5 1/4 Percent Convertible Subordinated Notes
Jun 16, 03
07:04 ET	Cephalon Appoints Dennis L. Winger to Board of Directors
Jun 12, 03
10:35 ET	Cephalon Announces Exercise of $150 Million Option On Convertible Subordinated Notes
Jun 06, 03
09:30 ET	Cephalon Prices $600 Million Convertible Subordinated Notes Offering
Jun 05, 03
16:29 ET	Cephalon Announces Proposed Convertible Subordinated Notes Offering
Jun 02, 03
09:31 ET	Cephalon Hires Michael Williams, Ph.D., D.Sc., Vice President, Worldwide Discovery Research
May 27, 03
19:30 ET	Offer Period Expires on Cephalon's Bid for SIRTeX
May 20, 03
15:30 ET	Studies Demonstrate PROVIGIL Improves Symptoms of ADHD in Children
May 07, 03
16:31 ET	Cephalon, Inc. Reports First Quarter 2003 Financial Results
Apr 30, 03
16:06 ET	Cephalon Quarterly Conference Call Invitation
Apr 02, 03
14:36 ET	Cephalon Transfers Manufacture of ACTIQ(R) to its Salt Lake City Facility; Formulation Change Approved for U.S. Market by FDA
11:30 ET	Cephalon Quarterly Conference Call Invitation
Mar 31, 03
07:01 ET	Cephalon, Inc. Files Patent Infringement Lawsuit Against Generic Companies
Mar 18, 03
07:00 ET	Cephalon, Inc. and Tanabe Seiyaku Announce License Agreement for ACTIQ in Japan
Feb 25, 03
09:00 ET	Cephalon Announces Executive Appointments; Vice Presidents Named in Project Management and Trade Relations
Feb 19, 03
16:30 ET	Cephalon, Inc. Reports 2002 Financial Results; Results Exceed Sales and Earnings Expectations; 2002 Revenue Tops One Half Billion Dollars; ACTIQ Leads Sales Growth
Feb 11, 03
19:32 ET	Cephalon, Inc. Announces Cash Bid to Acquire SIRTeX Medical Limited
11:30 ET	Cephalon Quarterly Conference Call Invitation
Feb 05, 03
17:18 ET	Cephalon, Inc. Learns of Generic Modafinil Filing; Company Intends to Vigorously Defend the Product's 2014 Patent
Jan 17, 03
11:30 ET	Cephalon Quarterly Conference Call Invitation
Dec 23, 02
08:00 ET	Cephalon Submits Supplemental New Drug Application for PROVIGIL
Dec 18, 02
13:29 ET	Cephalon Reacquires Rights to Modafinil in Major European Markets
Dec 03, 02
13:30 ET	Cephalon Receives Approval to Expand Marketing of Provigil in the United Kingdom
Nov 06, 02
16:31 ET	Cephalon, Inc. Reports Third Quarter 2002 Financial Results
Oct 23, 02
07:45 ET	Cephalon Announces Positive Results of PROVIGIL Clinical Study In Shift Work Sleep Disorder
Oct 11, 02
10:21 ET	Joseph S. Turi, Ph.D. Named Vice President, Worldwide Drug Development at Cephalon
Oct 08, 02
09:39 ET	Cephalon Quarterly Conference Call Invitation
Oct 03, 02
02:00 ET	Cephalon Reacquires Rights to ACTIQ(R) in Key European Markets; Deal Further Strengthens International Marketing Presence
Sep 16, 02
16:45 ET	Cephalon Announces Positive Results from a Study of PROVIGIL in Children with Attention Deficit Hyperactivity Disorder (ADHD)
Aug 30, 02
08:02 ET	Cephalon Announces Modafinil Receives Marketing Clearance In Australia, New Zealand and South Korea
Aug 05, 02
16:32 ET	Cephalon, Inc. Reports Second Quarter 2002 Financial Results
Aug 01, 02
08:02 ET	Cephalon and H. Lundbeck Initiate Clinical Trial In Patients With Early Stage Parkinson's Disease
Jul 29, 02
14:00 ET	Cephalon Quarterly Conference Call Invitation
Jul 18, 02
15:59 ET	H. LeRoux Jooste Named Vice President, Worldwide Product Planning at Cephalon
Jul 08, 02
13:34 ET	Cephalon Quarterly Conference Call Invitation
Jun 24, 02
07:02 ET	Cephalon and TransTech Pharma Initiate Drug Discovery Collaboration
Jun 13, 02
14:00 ET	Unethical Media Practices Revealed by IPRA Report
May 29, 02
14:13 ET	Cephalon Appoints Dr. Gail Wilensky to Board of Directors
May 06, 02
16:30 ET	Cephalon, Inc. Reports First Quarter 2002 Financial Results
Apr 29, 02
09:02 ET	Cephalon Quarterly Conference Call Invitation
Apr 17, 02
14:00 ET	Franck P. Kiser Named Vice President, Worldwide Drug Delivery Technologies at Cephalon
Apr 09, 02
14:38 ET	Cephalon Quarterly Conference Call Invitation
Apr 01, 02
08:20 ET	Cephalon Ends Marketing and Sales Joint Venture; Earnings Guidance Remains Unchanged
Mar 28, 02
08:04 ET	Cephalon Files Application Seeking Additional Indication For PROVIGIL in the United Kingdom
Mar 25, 02
09:22 ET	Cephalon Announces Executive Appointments; Vice Presidents Named in Business Development and IT&S
Feb 19, 02
16:30 ET	Cephalon, Inc. Reports 2001 Financial Results
Feb 11, 02
11:24 ET	Cephalon Quarterly Conference Call Invitation
Jan 22, 02
08:02 ET	Cephalon Announces Modafinil Receives Marketing Approval in Mexico
Jan 17, 02
11:32 ET	Alain Aragues Joins Laboratoire L. Lafon as President and Director General; Cephalon, Inc. Chooses an Industry Veteran to Lead Its Newly Acquired Company
Jan 11, 02
14:52 ET	Cephalon Quarterly Conference Call Invitation; 2001 Fourth Quarter Earnings Conference Call Tuesday, February 19, 2002, 5:00 p.m. U.S. EST
Jan 08, 02
17:00 ET	Cephalon Strengthens Its Global Presence By Acquiring International Rights to GABITRIL
Dec 28, 01
14:23 ET	Cephalon, Inc. Completes Acquisition of France's Group Lafon
Dec 20, 01
10:45 ET	Cephalon, Inc. Announces New Marketing and Sales Venture
08:00 ET	Cephalon and Sanofi-Synthelabo Form Partnership for Worldwide Development and Marketing of Novel Angiogenesis Inhibitors
Dec 17, 01
10:17 ET	Cephalon, Inc. Added to the Nasdaq-100 Index
Dec 11, 01
08:47 ET	Cephalon Announces Exercise of $100 Million Option on Convertible Subordinated Notes
Dec 06, 01
06:57 ET	Cephalon, Inc. Announces Private Placement Of $500 Million of Convertible Subordinated Notes
Dec 04, 01
16:49 ET	Cephalon, Inc. to Pursue $300 Million Offering of Convertible Subordinated Notes
Dec 03, 01
06:23 ET	Cephalon Conference Call Invitation
06:13 ET	Cephalon, Inc. Plans to Acquire France's Group Lafon
Nov 14, 01
08:04 ET	Cephalon Reports that Data Show that CEP-1347 Increased Success Of Brain Cell Transplantation in Models of Parkinson's Disease
Nov 05, 01
16:32 ET	Cephalon, Inc. Reports Third Quarter 2001 Financial Results
Nov 02, 01
08:01 ET	American Journal of Respiratory and Critical Care Medicine Publishes Study On Adjunct Use of Unique Wake-Promoting Agent in Obstructive Sleep Apnea
Oct 18, 01
12:19 ET	Cephalon Quarterly Conference Call Invitation
Oct 09, 01
07:42 ET	Study Demonstrates That Cephalon's PROVIGIL Significantly Improves Wakefulness in Patients With Obstructive Sleep Apnea